Noninvasive Cancer Diagnostics: Technologies and Global Markets
The global market for noninvasive cancer diagnostics was valued at $107.4 billion in 2016. This market is estimated to grow from nearly $114.6 billion in 2017 to $159.8 billion by 2022 with a compound annual growth rate (CAGR) of 6.9% for the period of 2017-2022.
Diagnostic imaging technologies, the leading segment of this market, will grow from $43.6 billion in 2017 to $58.5 billion by 2022 with a CAGR of 6.1%.
The market for advanced noninvasive approaches will grow from $40.5 billion in 2017 to $57.9 billion by 2022 with a CAGR of 7.4%.
Diagnostic imaging technologies, the leading segment of this market, will grow from $43.6 billion in 2017 to $58.5 billion by 2022 with a CAGR of 6.1%.
The market for advanced noninvasive approaches will grow from $40.5 billion in 2017 to $57.9 billion by 2022 with a CAGR of 7.4%.
CHAPTER 1: INTRODUCTION
Study Goals and Objectives
Scope of Report
Methodology and Information Sources
Primary Data and Information Gathering
Secondary Data and Information Gathering
Market Share Analysis and Market Forecast Prediction
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2: SUMMARY AND HIGHLIGHTS
Summary of Key Findings
Diagnostic Imaging Segment
Advanced Diagnostics Segment
Conventional Segment
CHAPTER 3: MARKET AND TECHNOLOGY REVIEW: DIAGNOSTIC IMAGING
Realtime In Vivo Cancer Diagnosis using Raman Spectroscopy
InVivo Fluorescence Imaging in Personalized Cancer Diagnostics
Direct Imaging
Indirect Fluorescence Imaging
Magnetic Resonance Imaging (MRI) Scans
Development to the RF Subsystem
Positron Emission Tomography (PET) Scan
Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Mammography
Digital Mammography Systems
Breast Tomosynthesis Systems
Ultrasound
Barium Swallow or Enema
Bone Scans (MRI, CT and PET)
Market Estimate
CHAPTER 4: MARKET AND TECHNOLOGY REVIEW: ADVANCED NONINVASIVE CANCER
Diagnostic Assays and Technologies
Introduction to Circulating Nucleic Acids (CNAs)
Circulating Nucleic Acids as a Diagnostic Tool
Circulating DNA as a Biomarker of Cancer
Use of Circulating DNA for Prenatal Diagnosis (Conventional)
Use of Circulating DNA for Prenatal Diagnosis (Noninvasive)
Circulating RNA as a Biomarker of Cancer
Methods Used for the Detection of Circulating Nucleic Acids
Liquid Biopsy
Janssen Diagnostics
Roche Molecular Systems Inc.
Genomic Health
Foundation Medicine
Veracyte 60Trovagene Inc.
Myriad Genetics
OncoCyte Corp.
Illumina
NeoGenomics Laboratories
Biocept Inc.
Vermillion Inc.
Sysmex Inostics, a subsidiary of Sysmex Corp.
Guardant Health
Product Development and New Initiatives in Liquid Biopsy
Molecular Cytogenetic/Gene Expression Studies
Amplify and Detect Diminished Amounts of RNA Consistently
Analyze Hundreds of Genes
Proteomics and New Protein Markers
Inside the ProteinChip System
Proteome Pattern Recognition
NextGeneration Sequencing (NGS) Studies
Illumina Solexa System
Roche 454 Sequencing
Thermo Fisher Scientific Ion Personal Genome Machine (PGM)
Thermo Fisher Scientific SOLiD (Sequencing by Oligonucleotide Ligation and Detection)
Oxford Nanopore Technologies
The ThirdGeneration Sequencer
Clinical Acceptance of a New Diagnostic Assay
SalivaBased Oral Cancer Diagnostics
Advanced Tissue Staining (Immunohistochemistry (IHC) and in situ Hybridization (ISH))
Optical Biopsy
Market Estimate
CHAPTER 5: MARKET AND TECHNOLOGY REVIEW: CONVENTIONAL NONINVASIVE CANCER
Diagnostic Assays and Tests
Pap Test and HPV Testing
Tumor Biomarker Testing
MammaPrint Specifications
Genomic Health’s Oncotype DX Breast Cancer Test
The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test)
Sales and Marketing Strategies for Cancer Tests
Fecal Occult Blood Tests (FOBT)
Digital Rectal Exam (DRE)
Multigated Acquisition (MUGA) Scans
Market Estimate
CHAPTER 6: INCIDENCE, PREVALENCE AND MORTALITY STATISTICS FOR CANCER: A GLOBAL
Summary
Cancer: The Disease
Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
Incidence and Prevalence Rates for Major Cancer Types
Regional Patterns of Cancer
Europe
North America
AsiaPacific
Latin and Central America
Middle East/Africa
The Global Cancer Burden and Worldwide Cancer Risk Factors
Tobacco Use and Statistics
Alcohol Abuse and Cancer Statistics
Obesity and Cancer Statistics
Infectious Diseases and Cancer
Inherited Genes/Diseases and Cancer
Sun, U.V. and Cancer
Hormones and Cancer
CHAPTER 7: NONINVASIVE CANCER DIAGNOSTICS MARKET BY CANCER TYPE
Global Noninvasive Cancer Diagnostics Market, by Cancer Type
Global Market Drivers
Global Market Restraints
Regional Noninvasive Cancer Diagnostics Market Assessment: North America
Selected Market Drivers: North America
Selected Market Restraints: North America
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type
Regional Noninvasive Cancer Diagnostics Market Assessment: Europe
Selected Market Drivers: Europe
Selected Market Restraint: Europe
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type
Regional Noninvasive Cancer Diagnostics Market Assessment: AsiaPacific
Selected Market Drivers: AsiaPacific
Selected Market Restraints: AsiaPacific
Regional Noninvasive Cancer Diagnostics Market Assessment: Central and Latin America
Selected Market Drivers: Central and Latin America
Selected Market Restraints: Central and Latin America
Regional Noninvasive Cancer Diagnostics Market Assessment: Middle East/Africa
Selected Market Drivers: Middle East/Africa
Selected Market Restraints: Middle East/Africa
CHAPTER 8: MARKET ANALYSIS BY TECHNOLOGY, END USER AND MARKET SHARE
Global Noninvasive Cancer Diagnostics Market, by Technology
Regional Noninvasive Cancer Diagnostics Market, by Technology: North America
Regional Noninvasive Cancer Diagnostics Market, by Technology: Europe
Regional Noninvasive Cancer Diagnostics Market, by Technology: AsiaPacific
Regional Noninvasive Cancer Diagnostics Market, by Technology: Central and Latin America
Regional Noninvasive Cancer Diagnostics Market, by Technology: Middle East/Africa
Global Noninvasive Cancer Diagnostics Market, by EndUser
General Clinical Reference Laboratories
Market Share Analysis by Technology: Noninvasive Cancer Diagnostics Market
CHAPTER 9: TECHNOLOGICAL ADVANCES, TRENDS AND OPPORTUNITIES
Key Technological Developments and Advances, Market Trends and Opportunities
Developments and Advances, Trends and Opportunities in Diagnostic Imaging
Developments and Advances, Trends and Opportunities in Advanced Noninvasive Approaches
Developments and Advances, Trends and Opportunities in Screening Assays
Opportunities for IVDMIA Companies
CHAPTER 10: REGULATORY AND LEGISLATIVE REQUIREMENTS
United States
How are IVDs Classified?
FDA Regulations Relating to Companion Diagnostics
Laboratory Developed Tests (LDTs)
Centers for Medicare & Medicaid Services (CMS)
The 2010 Affordable Care Act
Private Insurance
Europe 231 (General) Medical Device Directive, MDD (93/42/EEC)
Active Implantable Medical Device Directive, AIMDD (90/383/EEC
In Vitro Diagnostic Medical Device Directive, IVDMDD (98/79/EC)
Proposal for Changes to the Medical Device Directive, MDD (93/42/EEC)
Japan
Marketing Authorization System
China
Overview of the Healthcare System
Healthcare Reforms
Healthcare Institutions
India
Overview of the Healthcare System
Hospital Resources
Population Statistics
South Korea
Brazil
Background
Regulatory and Legislative Requirements
Market Entry and Reimbursement of Medical Devices: Brazil
Argentina
Background
Governmentfunded Public Health Sector
Social Health Insurance Sector
Private Sector
Regulatory and Legislative Requirements
Mexico
Legislation and Regulations Governing Medical Devices in Mexico
Health Insurance Structure in Mexico
CHAPTER 11: PATENT REVIEW OF KEY TECHNOLOGIES
Microarray Patents
LOAC Patents
Clinical NextGeneration Sequencing (NGS) Patents
Clinical NGS Patents Summary
Clinical NGS Patents by Indication
CHAPTER 12: COMPANY PROFILES
Appendix A: Company Addresses and Contact Details
Appendix B: Government Regulatory Agencies and Professional Organizations
Appendix C: Commonly Used Acronym Associated with Noninvasive Cancer
Diagnostics
About BCC Research
About BCC Research
BCC Membership
BCC Custom Research
Study Goals and Objectives
Scope of Report
Methodology and Information Sources
Primary Data and Information Gathering
Secondary Data and Information Gathering
Market Share Analysis and Market Forecast Prediction
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2: SUMMARY AND HIGHLIGHTS
Summary of Key Findings
Diagnostic Imaging Segment
Advanced Diagnostics Segment
Conventional Segment
CHAPTER 3: MARKET AND TECHNOLOGY REVIEW: DIAGNOSTIC IMAGING
Realtime In Vivo Cancer Diagnosis using Raman Spectroscopy
InVivo Fluorescence Imaging in Personalized Cancer Diagnostics
Direct Imaging
Indirect Fluorescence Imaging
Magnetic Resonance Imaging (MRI) Scans
Development to the RF Subsystem
Positron Emission Tomography (PET) Scan
Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Mammography
Digital Mammography Systems
Breast Tomosynthesis Systems
Ultrasound
Barium Swallow or Enema
Bone Scans (MRI, CT and PET)
Market Estimate
CHAPTER 4: MARKET AND TECHNOLOGY REVIEW: ADVANCED NONINVASIVE CANCER
Diagnostic Assays and Technologies
Introduction to Circulating Nucleic Acids (CNAs)
Circulating Nucleic Acids as a Diagnostic Tool
Circulating DNA as a Biomarker of Cancer
Use of Circulating DNA for Prenatal Diagnosis (Conventional)
Use of Circulating DNA for Prenatal Diagnosis (Noninvasive)
Circulating RNA as a Biomarker of Cancer
Methods Used for the Detection of Circulating Nucleic Acids
Liquid Biopsy
Janssen Diagnostics
Roche Molecular Systems Inc.
Genomic Health
Foundation Medicine
Veracyte 60Trovagene Inc.
Myriad Genetics
OncoCyte Corp.
Illumina
NeoGenomics Laboratories
Biocept Inc.
Vermillion Inc.
Sysmex Inostics, a subsidiary of Sysmex Corp.
Guardant Health
Product Development and New Initiatives in Liquid Biopsy
Molecular Cytogenetic/Gene Expression Studies
Amplify and Detect Diminished Amounts of RNA Consistently
Analyze Hundreds of Genes
Proteomics and New Protein Markers
Inside the ProteinChip System
Proteome Pattern Recognition
NextGeneration Sequencing (NGS) Studies
Illumina Solexa System
Roche 454 Sequencing
Thermo Fisher Scientific Ion Personal Genome Machine (PGM)
Thermo Fisher Scientific SOLiD (Sequencing by Oligonucleotide Ligation and Detection)
Oxford Nanopore Technologies
The ThirdGeneration Sequencer
Clinical Acceptance of a New Diagnostic Assay
SalivaBased Oral Cancer Diagnostics
Advanced Tissue Staining (Immunohistochemistry (IHC) and in situ Hybridization (ISH))
Optical Biopsy
Market Estimate
CHAPTER 5: MARKET AND TECHNOLOGY REVIEW: CONVENTIONAL NONINVASIVE CANCER
Diagnostic Assays and Tests
Pap Test and HPV Testing
Tumor Biomarker Testing
MammaPrint Specifications
Genomic Health’s Oncotype DX Breast Cancer Test
The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test)
Sales and Marketing Strategies for Cancer Tests
Fecal Occult Blood Tests (FOBT)
Digital Rectal Exam (DRE)
Multigated Acquisition (MUGA) Scans
Market Estimate
CHAPTER 6: INCIDENCE, PREVALENCE AND MORTALITY STATISTICS FOR CANCER: A GLOBAL
Summary
Cancer: The Disease
Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
Incidence and Prevalence Rates for Major Cancer Types
Regional Patterns of Cancer
Europe
North America
AsiaPacific
Latin and Central America
Middle East/Africa
The Global Cancer Burden and Worldwide Cancer Risk Factors
Tobacco Use and Statistics
Alcohol Abuse and Cancer Statistics
Obesity and Cancer Statistics
Infectious Diseases and Cancer
Inherited Genes/Diseases and Cancer
Sun, U.V. and Cancer
Hormones and Cancer
CHAPTER 7: NONINVASIVE CANCER DIAGNOSTICS MARKET BY CANCER TYPE
Global Noninvasive Cancer Diagnostics Market, by Cancer Type
Global Market Drivers
Global Market Restraints
Regional Noninvasive Cancer Diagnostics Market Assessment: North America
Selected Market Drivers: North America
Selected Market Restraints: North America
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type
Regional Noninvasive Cancer Diagnostics Market Assessment: Europe
Selected Market Drivers: Europe
Selected Market Restraint: Europe
Selected Country: Noninvasive Cancer Diagnostics Market, by Cancer Type
Regional Noninvasive Cancer Diagnostics Market Assessment: AsiaPacific
Selected Market Drivers: AsiaPacific
Selected Market Restraints: AsiaPacific
Regional Noninvasive Cancer Diagnostics Market Assessment: Central and Latin America
Selected Market Drivers: Central and Latin America
Selected Market Restraints: Central and Latin America
Regional Noninvasive Cancer Diagnostics Market Assessment: Middle East/Africa
Selected Market Drivers: Middle East/Africa
Selected Market Restraints: Middle East/Africa
CHAPTER 8: MARKET ANALYSIS BY TECHNOLOGY, END USER AND MARKET SHARE
Global Noninvasive Cancer Diagnostics Market, by Technology
Regional Noninvasive Cancer Diagnostics Market, by Technology: North America
Regional Noninvasive Cancer Diagnostics Market, by Technology: Europe
Regional Noninvasive Cancer Diagnostics Market, by Technology: AsiaPacific
Regional Noninvasive Cancer Diagnostics Market, by Technology: Central and Latin America
Regional Noninvasive Cancer Diagnostics Market, by Technology: Middle East/Africa
Global Noninvasive Cancer Diagnostics Market, by EndUser
General Clinical Reference Laboratories
Market Share Analysis by Technology: Noninvasive Cancer Diagnostics Market
CHAPTER 9: TECHNOLOGICAL ADVANCES, TRENDS AND OPPORTUNITIES
Key Technological Developments and Advances, Market Trends and Opportunities
Developments and Advances, Trends and Opportunities in Diagnostic Imaging
Developments and Advances, Trends and Opportunities in Advanced Noninvasive Approaches
Developments and Advances, Trends and Opportunities in Screening Assays
Opportunities for IVDMIA Companies
CHAPTER 10: REGULATORY AND LEGISLATIVE REQUIREMENTS
United States
How are IVDs Classified?
FDA Regulations Relating to Companion Diagnostics
Laboratory Developed Tests (LDTs)
Centers for Medicare & Medicaid Services (CMS)
The 2010 Affordable Care Act
Private Insurance
Europe 231 (General) Medical Device Directive, MDD (93/42/EEC)
Active Implantable Medical Device Directive, AIMDD (90/383/EEC
In Vitro Diagnostic Medical Device Directive, IVDMDD (98/79/EC)
Proposal for Changes to the Medical Device Directive, MDD (93/42/EEC)
Japan
Marketing Authorization System
China
Overview of the Healthcare System
Healthcare Reforms
Healthcare Institutions
India
Overview of the Healthcare System
Hospital Resources
Population Statistics
South Korea
Brazil
Background
Regulatory and Legislative Requirements
Market Entry and Reimbursement of Medical Devices: Brazil
Argentina
Background
Governmentfunded Public Health Sector
Social Health Insurance Sector
Private Sector
Regulatory and Legislative Requirements
Mexico
Legislation and Regulations Governing Medical Devices in Mexico
Health Insurance Structure in Mexico
CHAPTER 11: PATENT REVIEW OF KEY TECHNOLOGIES
Microarray Patents
LOAC Patents
Clinical NextGeneration Sequencing (NGS) Patents
Clinical NGS Patents Summary
Clinical NGS Patents by Indication
CHAPTER 12: COMPANY PROFILES
Appendix A: Company Addresses and Contact Details
Appendix B: Government Regulatory Agencies and Professional Organizations
Appendix C: Commonly Used Acronym Associated with Noninvasive Cancer
Diagnostics
About BCC Research
About BCC Research
BCC Membership
BCC Custom Research
LIST OF TABLES
Summary Table Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 1 Diagnostic Imaging Segment
Table 2 Advanced Segment
Table 3 Conventional Segment
Table 4 Noninvasive Cancer Diagnostics Market Segmentation
Table 5 Breast MRI Systems Currently Available
Table 6 Wide Bore MRI Systems Currently Available
Table 7 PET/CT Systems Currently Available
Table 8 PET/MR Systems Currently Available
Table 9 Key trends in (Digital Mammography Systems)
Table 10 Digital Mammography Systems Currently Available
Table 11 Breast Tomosynthesis Systems Currently Available
Table 12 Benefits of Medical Ultrasound Imaging
Table 13 Regulatory Approval for Highintensity Focused Ultrasound (HIFU) by Region
Table 14 Ultrasound Systems Currently Available
Table 15 Noninvasive Cancer Diagnostics Market Segmentation
Table 16 Major Developments in Understanding Nucleic Acids and their Cellular Roles
Table 17 Circulating Tumorassociated miRNAs as Potential Cancer Biomarkers
Table 18 Key Elements for Business Competition in Gene Expression Profiling for Cancer
Table 19 DNA Microarray Diagnostic Test Adoption Rate
Table 20 Characteristics of in situ Hybridization Methods
Table 21 Key Advantages of Optical Biopsy Systems
Table 22 Noninvasive Cancer Diagnostics Market Segmentation
Table 23 Key Drivers to Adoption of Biomarkers in Clinical Use
Table 24 Key Barriers to Adoption of Biomarkers in Clinical Use
Table 25 Tumor Biomarkers Currently in Common Clinical Use
Table 26 MammaPrint: Key Features
Table 27 Strategies for Marketing Cancer Diagnostic Products
Table 28 Advantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))
Table 29 Disadvantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))
Table 30 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear Prevalence, 2012
Table 31 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear Prevalence (In Men and Women Combined) by Cancer Type, 2012
Table 32 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear Prevalence (Men) by Cancer Type, 2012
Table 33 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear Prevalence (Women) by Cancer Type, 2012
Table 34 Estimated Number of New Cancer Cases by Sex: United States, 2017 (%)
Table 35 Estimated Number of Deaths from Cancer by Sex: United States, 2017
Table 36 Global Noninvasive Cancer Diagnostics Market, Through 2022 ($ Millions)
Table 37 Global Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 38 Global Noninvasive Cancer Diagnostics Market and Market Share, by Cancer Type, 2017 (%)
Table 39 Global Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Table 40 North American Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 41 Sample Listing of Payers that Published Positive Coverage Policies for KRAS Testing
Table 42 United States Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 43 Canada Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 44 European Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 45 Europe: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Table 46 France Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 47 Germany Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 48 Italy Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 49 Spain Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 50 U.K. Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 51 Benelux Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 52 Scandinavia Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 53 Rest of Europe Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 54 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 55 AsiaPacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Table 56 China: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 57 India: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions)
Table 58 Japan: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions)
Table 59 South Korea: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 60 Rest of AsiaPacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 61 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 62 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Table 63 Argentina: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 64 Brazil: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 65 Chile: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 66 Mexico: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)170
Table 67 Rest of Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 68 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 69 Middle East/Africa: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Table 70 Middle East: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 71 Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 72 Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 73 Global Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 74 Global Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 75 Global Noninvasive Cancer Diagnostics Market, by Conventional Noninvasive Cancer Screening and Diagnostic Assays and Tests Technology, Through 2022 ($ Millions)
Table 76 North America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 77 North American: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 78 North American: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 79 North American: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 80 Europe: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 81 Europe: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 82 Europe: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 83 Europe: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 84 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 85 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 86 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 87 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 88 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 89 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 90 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 91 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 92 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 93 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 94 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 95 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 96 Global Noninvasive Cancer Diagnostics Market, by EndUser, Through 2022 ($ Millions)
Table 97 Global Market Share for Diagnostic Imaging, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 98 Global Market Share for Advanced Noninvasive Approaches, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 99 Global Market Share for Molecular SignatureBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 100 Global Market Share for DNA MicroarrayBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 101 Global Market Share for Cytogenetic/Gene ExpressionBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 102 Global Market Share for Circulating Nucleic Acid (CNA)Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 103 Global Market Share for Screening Assays, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 104 Global Market Share for Fecal Occult Blood Test (FOBT)Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 105 Global Market Share for Tumor Biomarker TestBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 106 Principal Factors Influencing the Growth and Development of Noninvasive Cancer Diagnostics, 2017
Table 107 Uses of Tumor Biomarkers in Drug Development
Table 108 Utility of Biomarkers as Companion Diagnostics to Drug Development
Table 109 Overview of Pharmaceutical Affair Law (PAL) and Japanese Medical Device Nomenclature (JMDN) Codes and Related Codes according to the EU MDD
Table 110 Number of Healthcare Institutions According to Ownership in China, 2010
Table 111 Total Number of Hospitals by Ranking in China, 2010
Table 112 Overview of Healthcare in India
Table 113 DNA Microarray Patents by Region, 20022012
Table 114 MicroarrayRelated Proteomics Patents by Region, 2002 – 2012
Table 115 MicroarrayRelated Patents by Application and Title, 2017
Table 116 Patent Application and Title: Noninvasive Cancer Diagnostics, 2001 – Present
Table 117 LOACRelated Proteomics Patents by Region, 2002 – 2012
Table 118 LOACRelated Patents by Application and Title, 2013 – 2015
Table 119 Clinical Next Generation Sequencing Patents, 2002–2012
Table 120 Clinical NGSRelated Patents by Application and Title, 2013 – 2015
Table 121 Clinical NGS Patents by Indication, 2002–2012
Table 122 Abbott Laboratories: Company Financials, Through 2016 ($ Millions)
Table 123 Bayer AG: Company Financials, Through 2016 ($ Millions)
Table 124 bioMerieux S.A. Sales by Application, Through 2016 ($ Millions)
Table 125 Exact Sciences Corp.: Company Financials, Through 2016 ($ Millions/%)
Table 126 Hologic Inc.: Company Financials, 20152016 ($ Millions)
Table 127 Illumina, Inc: Company Financials, 20142016 ($ Millions)
Table 128 Myriad Genetics Inc. Financials, 2014 2016 ($ Millions)
Table 129 Philips Healthcare Financials, Through 2016 ($ Millions)
Table 130 Philips Group Financials by Segment, 2016 ($ Millions)
Table 131 Qiagen N.V. Financials, Through 2016 ($ Millions)
Table 132 Qiagen N.V. Financials by Region, Through 2016 ($ Millions)
Table 133 Quest Diagnostics Financials, Through 2016 ($ Millions)
Table 134 Roche Group Financials, Through 2016 ($ Millions) 322Table 135 Diagnostics Division Financials, 2015 and 2016 ($ Millions)
Table 136 Thermo Fisher Scientific Inc. Financials, Through 2016 ($ Millions)
Table 137 Company Addresses and Contact Details
Table 138 Government Regulatory Agencies and Professional Organizations Associated with Noninvasive Cancer Diagnostics
Table 139 Commonly Used Acronym Associated with Noninvasive Cancer Diagnostics
Summary Table Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 1 Diagnostic Imaging Segment
Table 2 Advanced Segment
Table 3 Conventional Segment
Table 4 Noninvasive Cancer Diagnostics Market Segmentation
Table 5 Breast MRI Systems Currently Available
Table 6 Wide Bore MRI Systems Currently Available
Table 7 PET/CT Systems Currently Available
Table 8 PET/MR Systems Currently Available
Table 9 Key trends in (Digital Mammography Systems)
Table 10 Digital Mammography Systems Currently Available
Table 11 Breast Tomosynthesis Systems Currently Available
Table 12 Benefits of Medical Ultrasound Imaging
Table 13 Regulatory Approval for Highintensity Focused Ultrasound (HIFU) by Region
Table 14 Ultrasound Systems Currently Available
Table 15 Noninvasive Cancer Diagnostics Market Segmentation
Table 16 Major Developments in Understanding Nucleic Acids and their Cellular Roles
Table 17 Circulating Tumorassociated miRNAs as Potential Cancer Biomarkers
Table 18 Key Elements for Business Competition in Gene Expression Profiling for Cancer
Table 19 DNA Microarray Diagnostic Test Adoption Rate
Table 20 Characteristics of in situ Hybridization Methods
Table 21 Key Advantages of Optical Biopsy Systems
Table 22 Noninvasive Cancer Diagnostics Market Segmentation
Table 23 Key Drivers to Adoption of Biomarkers in Clinical Use
Table 24 Key Barriers to Adoption of Biomarkers in Clinical Use
Table 25 Tumor Biomarkers Currently in Common Clinical Use
Table 26 MammaPrint: Key Features
Table 27 Strategies for Marketing Cancer Diagnostic Products
Table 28 Advantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))
Table 29 Disadvantages of Fecal Occult Blood Test (Guaiac FOBT or Fecal Immunochemical Test (FIT))
Table 30 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear Prevalence, 2012
Table 31 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear Prevalence (In Men and Women Combined) by Cancer Type, 2012
Table 32 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear Prevalence (Men) by Cancer Type, 2012
Table 33 Summary Statistics (Global): Estimated Incidence, Mortality and FiveYear Prevalence (Women) by Cancer Type, 2012
Table 34 Estimated Number of New Cancer Cases by Sex: United States, 2017 (%)
Table 35 Estimated Number of Deaths from Cancer by Sex: United States, 2017
Table 36 Global Noninvasive Cancer Diagnostics Market, Through 2022 ($ Millions)
Table 37 Global Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 38 Global Noninvasive Cancer Diagnostics Market and Market Share, by Cancer Type, 2017 (%)
Table 39 Global Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Table 40 North American Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 41 Sample Listing of Payers that Published Positive Coverage Policies for KRAS Testing
Table 42 United States Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 43 Canada Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 44 European Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 45 Europe: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Table 46 France Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 47 Germany Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 48 Italy Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 49 Spain Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 50 U.K. Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 51 Benelux Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 52 Scandinavia Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 53 Rest of Europe Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 54 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 55 AsiaPacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Table 56 China: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 57 India: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions)
Table 58 Japan: Noninvasive Cancer Diagnostics Market, by Cancer Type, through 2022 ($ Millions)
Table 59 South Korea: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 60 Rest of AsiaPacific: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 61 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 62 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Table 63 Argentina: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 64 Brazil: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 65 Chile: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 66 Mexico: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)170
Table 67 Rest of Central and Latin America: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 68 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 69 Middle East/Africa: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Table 70 Middle East: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 71 Africa: Noninvasive Cancer Diagnostics Market, by Cancer Type, Through 2022 ($ Millions)
Table 72 Global Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 73 Global Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 74 Global Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 75 Global Noninvasive Cancer Diagnostics Market, by Conventional Noninvasive Cancer Screening and Diagnostic Assays and Tests Technology, Through 2022 ($ Millions)
Table 76 North America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 77 North American: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 78 North American: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 79 North American: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 80 Europe: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 81 Europe: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 82 Europe: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 83 Europe: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 84 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 85 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 86 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 87 AsiaPacific: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 88 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 89 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 90 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 91 Central and Latin America: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 92 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Technology, Through 2022 ($ Millions)
Table 93 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Diagnostic Imaging Technologies, Through 2022 ($ Millions)
Table 94 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Advanced Noninvasive Technologies, Through 2022 ($ Millions)
Table 95 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Screening Assay Technology, Through 2022 ($ Millions)
Table 96 Global Noninvasive Cancer Diagnostics Market, by EndUser, Through 2022 ($ Millions)
Table 97 Global Market Share for Diagnostic Imaging, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 98 Global Market Share for Advanced Noninvasive Approaches, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 99 Global Market Share for Molecular SignatureBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 100 Global Market Share for DNA MicroarrayBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 101 Global Market Share for Cytogenetic/Gene ExpressionBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 102 Global Market Share for Circulating Nucleic Acid (CNA)Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 103 Global Market Share for Screening Assays, Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 104 Global Market Share for Fecal Occult Blood Test (FOBT)Based Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 105 Global Market Share for Tumor Biomarker TestBased Noninvasive Cancer Diagnostics, by Company, 2017 (%)
Table 106 Principal Factors Influencing the Growth and Development of Noninvasive Cancer Diagnostics, 2017
Table 107 Uses of Tumor Biomarkers in Drug Development
Table 108 Utility of Biomarkers as Companion Diagnostics to Drug Development
Table 109 Overview of Pharmaceutical Affair Law (PAL) and Japanese Medical Device Nomenclature (JMDN) Codes and Related Codes according to the EU MDD
Table 110 Number of Healthcare Institutions According to Ownership in China, 2010
Table 111 Total Number of Hospitals by Ranking in China, 2010
Table 112 Overview of Healthcare in India
Table 113 DNA Microarray Patents by Region, 20022012
Table 114 MicroarrayRelated Proteomics Patents by Region, 2002 – 2012
Table 115 MicroarrayRelated Patents by Application and Title, 2017
Table 116 Patent Application and Title: Noninvasive Cancer Diagnostics, 2001 – Present
Table 117 LOACRelated Proteomics Patents by Region, 2002 – 2012
Table 118 LOACRelated Patents by Application and Title, 2013 – 2015
Table 119 Clinical Next Generation Sequencing Patents, 2002–2012
Table 120 Clinical NGSRelated Patents by Application and Title, 2013 – 2015
Table 121 Clinical NGS Patents by Indication, 2002–2012
Table 122 Abbott Laboratories: Company Financials, Through 2016 ($ Millions)
Table 123 Bayer AG: Company Financials, Through 2016 ($ Millions)
Table 124 bioMerieux S.A. Sales by Application, Through 2016 ($ Millions)
Table 125 Exact Sciences Corp.: Company Financials, Through 2016 ($ Millions/%)
Table 126 Hologic Inc.: Company Financials, 20152016 ($ Millions)
Table 127 Illumina, Inc: Company Financials, 20142016 ($ Millions)
Table 128 Myriad Genetics Inc. Financials, 2014 2016 ($ Millions)
Table 129 Philips Healthcare Financials, Through 2016 ($ Millions)
Table 130 Philips Group Financials by Segment, 2016 ($ Millions)
Table 131 Qiagen N.V. Financials, Through 2016 ($ Millions)
Table 132 Qiagen N.V. Financials by Region, Through 2016 ($ Millions)
Table 133 Quest Diagnostics Financials, Through 2016 ($ Millions)
Table 134 Roche Group Financials, Through 2016 ($ Millions) 322Table 135 Diagnostics Division Financials, 2015 and 2016 ($ Millions)
Table 136 Thermo Fisher Scientific Inc. Financials, Through 2016 ($ Millions)
Table 137 Company Addresses and Contact Details
Table 138 Government Regulatory Agencies and Professional Organizations Associated with Noninvasive Cancer Diagnostics
Table 139 Commonly Used Acronym Associated with Noninvasive Cancer Diagnostics
LIST OF FIGURES
Summary Figure Global Noninvasive Cancer Diagnostics Market, by Technology, 20162022 ($ Millions)
Figure 1 Top Molecular CNA Characterization Techniques (%)
Figure 2 Market Growth and Evolution of MDx Cancer Biomarkers
Figure 3 Estimated Global Cancer Incidence Proportions by Major Sites, In Men and Women Combined, 2012 (%)
Figure 4 Estimated World Cancer Incidence Proportions by Major Sites, In Men, 2012 (%)
Figure 5 Estimated World Cancer Incidence Proportions by Major Sites, In Women, 2012 (%)
Figure 6 Global Market Share for Noninvasive Cancer Diagnostics, by Cancer Type, 2017 (%)
Figure 7 Global Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Figure 8 Average Number of New Cases per Year and AgeSpecific Incidence Rates for all Cancers in the U.K., 2012?2014
Figure 9 Europe: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Figure 10 AsiaPacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Figure 11 Central and Latin America: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Figure 12 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Figure 13 Global Noninvasive Cancer Diagnostics Market, by Technology Type, 20162022 ($ Millions)
Figure 14 Global Noninvasive Cancer Diagnostics Market, by EndUser, 20162022 ($ Millions)
Figure 15 Tumor Biomarker Developments and Market Applications (%)
Figure 16 Private Health Insurance Coverage among Persons Under 65 in United States, 2007–2011 (Millions/Percent)
Figure 17 The Chinese Healthcare System
Summary Figure Global Noninvasive Cancer Diagnostics Market, by Technology, 20162022 ($ Millions)
Figure 1 Top Molecular CNA Characterization Techniques (%)
Figure 2 Market Growth and Evolution of MDx Cancer Biomarkers
Figure 3 Estimated Global Cancer Incidence Proportions by Major Sites, In Men and Women Combined, 2012 (%)
Figure 4 Estimated World Cancer Incidence Proportions by Major Sites, In Men, 2012 (%)
Figure 5 Estimated World Cancer Incidence Proportions by Major Sites, In Women, 2012 (%)
Figure 6 Global Market Share for Noninvasive Cancer Diagnostics, by Cancer Type, 2017 (%)
Figure 7 Global Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Figure 8 Average Number of New Cases per Year and AgeSpecific Incidence Rates for all Cancers in the U.K., 2012?2014
Figure 9 Europe: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Figure 10 AsiaPacific: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Figure 11 Central and Latin America: Noninvasive Cancer Diagnostics Market Share, by Region, 2017 (%)
Figure 12 Middle East/Africa: Noninvasive Cancer Diagnostics Market, by Region, 2017 (%)
Figure 13 Global Noninvasive Cancer Diagnostics Market, by Technology Type, 20162022 ($ Millions)
Figure 14 Global Noninvasive Cancer Diagnostics Market, by EndUser, 20162022 ($ Millions)
Figure 15 Tumor Biomarker Developments and Market Applications (%)
Figure 16 Private Health Insurance Coverage among Persons Under 65 in United States, 2007–2011 (Millions/Percent)
Figure 17 The Chinese Healthcare System
